Multimodal therapy for complete regression of malignant melanoma using constrained nonlinear optimal dynamic inversion

Using a realistic nonlinear mathematical model for melanoma dynamics and the technique of optimal dynamic inversion (exact feedback linearization with static optimization), a multimodal automatic drug dosage strategy is proposed in this paper for complete regression of melanoma cancer in humans. The proposed strategy computes different drug dosages and gives a nonlinear state feedback solution for driving the number of cancer cells to zero. However, it is observed that when tumor is regressed to certain value, then there is no need of external drug dosages as immune system and other therapeutic states are able to regress tumor at a sufficiently fast rate which is more than exponential rate. As model has three different drug dosages, after applying dynamic inversion philosophy, drug dosages can be selected in optimized manner without crossing their toxicity limits. The combination of drug dosages is decided by appropriately selecting the control design parameter values based on physical constraints. The process is automated for all possible combinations of the chemotherapy and immunotherapy drug dosages with preferential emphasis of having maximum possible variety of drug inputs at any given point of time. Simulation study with a standard patient model shows that tumor cells are regressed from 2 x 107 to order of 105 cells because of external drug dosages in 36.93 days. After this no external drug dosages are required as immune system and other therapeutic states are able to regress tumor at greater than exponential rate and hence, tumor goes to zero (less than 0.01) in 48.77 days and healthy immune system of the patient is restored. Study with different chemotherapy drug resistance value is also carried out. (C) 2014 Elsevier Ltd. All rights reserved.

[1]  Ami Radunskaya,et al.  The dynamics of an optimally controlled tumor model: A case study , 2003 .

[2]  M. Perry.  The Chemotherapy Source Book , 1992, Annals of Internal Medicine.

[3]  Ugo Del Monte,et al.  Does the cell number 10(9) still really fit one gram of tumor tissue , 2009 .

[4]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[5]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[6]  J. Stark,et al.  Mathematical models of the balance between apoptosis and proliferation , 2002, Apoptosis.

[7]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[8]  S N Gardner,et al.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.

[9]  A. I. Zotin.  Thermodynamic bases of biological processes : physiological reactions and adaptations , 1990 .

[10]  Xin Liu,et al.  State and parameter estimation of the heat shock response system using Kalman and particle filters , 2012, Bioinform..

[11]  Weiping Li,et al.  Applied Nonlinear Control , 1991 .

[12]  S Chareyron,et al.  Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes. , 2009, Journal of theoretical biology.

[13]  Falk Schreiber,et al.  An improved constraint filtering technique for inferring hidden states and parameters of a biological model , 2013, Bioinform..

[14]  A. Khar,et al.  High intratumoural level of cytokines mediates efficient regression of a rat histiocytoma , 1997, Clinical and experimental immunology.

[15]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[16]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[17]  Dan L. Longo Bruce A. Chabner.  Cancer chemotherapy and biotherapy , 2013 .

[18]  Mangal Kothari,et al.  An optimal dynamic inversion-based neuro-adaptive approach for treatment of chronic myelogenous leukemia , 2007, Comput. Methods Programs Biomed..

[19]  Katsuhiko Ogata,et al.  Modern Control Engineering , 1970 .

[20]  G. Griffiths,et al.  Development of humanized antibodies as cancer therapeutics. , 2005, Methods.

[21]  Soldano Ferrone,et al.  Tumors as elusive targets of T-cell-based active immunotherapy. , 2003, Trends in immunology.

[22]  Metin U. Salamci,et al.  SDRE optimal control of drug administration in cancer treatment , 2010 .

[23]  Robert A. Gatenby,et al.  Modelling a new angle on understanding cancer , 2002, Nature.

[24]  A. Murugan,et al.  Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. , 2007, Mathematical biosciences.

[25]  A. Jerant,et al.  Early detection and treatment of skin cancer. , 2000, American family physician.

[26]  Luca Mesin,et al.  Modeling of the immune response: conceptual frameworks and applications , 2001 .

[27]  Xavier Golay,et al.  Amide proton transfer imaging of human brain tumors at 3T , 2006, Magnetic resonance in medicine.